Archive

Rutgers & Posch advised the shareholders of Lexerta, a leading provider of health, safety and environment (HSE) compliance software, on the sale of a majority stake to WeKomply, a leading Nordic compliance software company that is backed by private equity investor Via Equity.  With this transaction Lexerta can further develop and strengthen its business in the Netherlands, Belgium and across the rest of Europe. The team of Rutgers…

Rutgers & Posch advised the shareholders of Jobport, an AI-powered SaaS platform focused on sustainable employability, on the sale of Jobport to OAZ/Equivalance, the HR-platform backed by private equity investor Fields Group. Together, they create a leading tech-enabled HR services platform for employers with 500+ employees in the Netherlands, combining expertise in social security cost management, workforce development, grants and sustainable employability. The team of Rutgers & Posch…

Menopause is a life phase that affects nearly half of the female workforce. Recent research shows that eight out of ten women experience complaints during menopause, and for seven out of ten women, these complaints affect their work. Examples include hot flashes, sleep problems, fatigue, and loss of concentration. Yet, the topic often remains underexposed in the workplace: only 13% of women discuss their complaints with their supervisor,…

In our practice, we usually see commercial contracts in which receivables arising from these contracts are not assignable and/or cannot be pledged. The rationale is that parties do not want to be faced with a creditor other than the party they have contracted with. The consequence of a restriction clause is that the relevant receivables cannot be used as collateral in a financing transaction or transferred in the…

Rutgers & Posch advises Zorg van de Zaak, the company health network in the Netherlands, in relation to its disposal of Naviva Kraamzorg, one of the largest maternity care providers in the Netherlands, to Morefield, a subsidiary of investment company Value 8. The transaction is subject to regulatory approvals. The team of Rutgers & Posch consisted of Matthijs van den Broek, Inge de Laat, Veerle Cordemeijer, Hanna Steensma,…

Rutgers & Posch represented NASDAQ listed uniQure N.V. in respect of its $75 million fully underwritten public offering of new ordinary shares. uniQure is advancing a pipeline of proprietary gene therapies for the treatment of patients with Huntington’s disease, refractory temporal lobe epilepsy, ALS, Fabry disease, and other severe diseases. Bas Visée and Jamie Pellegrom advised uniQure. Rutgers & Posch teamed up with US firm Morgan Lewis. For…